Clinical trials in drug design
Nature Reviews Drug Discovery 5, 133-146 doi:10.1038/nrd1956
More than 50 years after the introduction of modern pharmacotherapies for schizophrenia, there remains a tremendous need for therapeutic advances. A second generation of antipsychotic drugs, introduced over the past 15 years, has provided uncertain advantages over the first-generation drugs. This paper reviews the designs of studies that evaluate the effectiveness of putative antipsychotic drugs. Data from the trials needed to achieve regulatory approval do not meet all the needs of clinicians and policy makers. Practical and large, simple trials that evaluate the comparative effectiveness of antipsychotic drugs in real-world settings can help to meet these needs once a drug has reached the market.
- Department of Psychiatry, University of North Carolina at Chapel Hill, CB 7160, Chapel Hill, North Carolina, USA.
- Valeant Pharmaceuticals International, 6363 Greenwich Drive, Suite 100, San Diego, California 92122, USA.
- Department of Psychiatry, Columbia University Medical Center, 1051 Riverside Drive, Unit 4, New York, New York 10032, USA.
You might also like
When Is IRB Review of Clinical Trial Websites Required?
When information posted on a clinical trial website goes beyond directory listings with basic descriptive information, such information is considered part of the informed consent process and therefore requires IRB review and approval. Basic descriptive information includes: